You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday. The latest on GSK’s AI research, MyChart message billing, & new role for UCSF digital health lead
After FDA nod, Better Therapeutics races to boost dwindling cash
Better Therapeutics has cleared one hurdle: The Food and Drug Administration last week authorized the company to market AspyreRx, its prescription app which uses CBT to treat type 2 diabetes. Better now needs money, and fast. The public company recently raised $6.5 million in a stock sale to supplement its existing reserves, but it’s on the hunt for a medical device or pharmaceutical company partner that can provide the capital needed to fuel commercialization. CEO Frank Karbe told me the company hopes to have a deal in place by the end of the year.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.